- Home
- IGR vs RIGL Comparison
IGR vs RIGL Comparison
Compare IGR & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IGR | RIGL |
|---|---|---|
| Founded | 2004 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 645.2M | 537.6M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | IGR | RIGL |
|---|---|---|
| Price | $4.56 | $46.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $43.20 |
| AVG Volume (30 Days) | ★ 747.7K | 567.7K |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 13.93% | N/A |
| EPS Growth | N/A | ★ 2698.26 |
| EPS | N/A | ★ 6.20 |
| Revenue | N/A | ★ $282,076,000.00 |
| Revenue This Year | N/A | $65.53 |
| Revenue Next Year | N/A | $0.22 |
| P/E Ratio | ★ N/A | $6.98 |
| Revenue Growth | N/A | ★ 79.13 |
| 52 Week Low | $3.88 | $15.50 |
| 52 Week High | $5.70 | $52.24 |
Technical Indicators
Market Signals| Indicator | IGR | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 60.37 | 61.34 |
| Support Level | $4.35 | $40.50 |
| Resistance Level | $4.42 | $43.56 |
| Average True Range (ATR) | 0.07 | 2.04 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 82.93 | 72.56 |
Price Performance
Historical ComparisonAbout IGR CBRE Global Real Estate Income Fund of Beneficial Interest
CBRE Clarion Global Real Estate Income Fund is a United States-based diversified, closed-end management investment company. Its primary objective is high current income, and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities, which includes common stocks, preferred securities, warrants, and convertible securities issued by real estate companies, such as real estate investment trusts. Under normal market conditions, it invests in real estate equity securities of companies domiciled predominantly in developed countries.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.